Cargando…

Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses

SARS-CoV-2 surface spike protein mediates the viral entry into the host cell and represents the primary immunological target of COVID-19 vaccines as well as post-exposure immunotherapy. Establishment of the highly immunogenic B-cell epitope profile of SARS-CoV-2 proteins in general, and that of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Levy, Yinon, Alcalay, Ron, Zvi, Anat, Makdasi, Efi, Peretz, Eldar, Noy-Porat, Tal, Chitlaru, Theodor, Mandelboim, Michal, Mazor, Ohad, Rosenfeld, Ronit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875268/
https://www.ncbi.nlm.nih.gov/pubmed/35214711
http://dx.doi.org/10.3390/vaccines10020251
_version_ 1784657877719318528
author Levy, Yinon
Alcalay, Ron
Zvi, Anat
Makdasi, Efi
Peretz, Eldar
Noy-Porat, Tal
Chitlaru, Theodor
Mandelboim, Michal
Mazor, Ohad
Rosenfeld, Ronit
author_facet Levy, Yinon
Alcalay, Ron
Zvi, Anat
Makdasi, Efi
Peretz, Eldar
Noy-Porat, Tal
Chitlaru, Theodor
Mandelboim, Michal
Mazor, Ohad
Rosenfeld, Ronit
author_sort Levy, Yinon
collection PubMed
description SARS-CoV-2 surface spike protein mediates the viral entry into the host cell and represents the primary immunological target of COVID-19 vaccines as well as post-exposure immunotherapy. Establishment of the highly immunogenic B-cell epitope profile of SARS-CoV-2 proteins in general, and that of the spike protein in particular, may contribute to the development of sensitive diagnostic tools and identification of vaccine` candidate targets. In the current study, the anti-viral antibody response in transgenic K18-hACE-2 mice was examined by implementing an immunodominant epitope mapping approach of the SARS-CoV-2 spike. Serum samples for probing an epitope array covering the entire spike protein were collected from mice following infection with the original SARS-CoV-2 strain as well as the B.1.1.7 Alpha and B.1.351 Beta genetic variants of concern. The analysis resulted in distinction of six linear epitopes common to the humoral response against all virus variants inspected at a frequency of more than 20% of the serum samples. Finally, the universality of the response was probed by cross-protective in vitro experiments using plaque-reducing neutralization tests. The data presented here has important implications for prediction of the efficacy of immune countermeasures against emerging SARS-CoV-2 variants.
format Online
Article
Text
id pubmed-8875268
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88752682022-02-26 Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses Levy, Yinon Alcalay, Ron Zvi, Anat Makdasi, Efi Peretz, Eldar Noy-Porat, Tal Chitlaru, Theodor Mandelboim, Michal Mazor, Ohad Rosenfeld, Ronit Vaccines (Basel) Article SARS-CoV-2 surface spike protein mediates the viral entry into the host cell and represents the primary immunological target of COVID-19 vaccines as well as post-exposure immunotherapy. Establishment of the highly immunogenic B-cell epitope profile of SARS-CoV-2 proteins in general, and that of the spike protein in particular, may contribute to the development of sensitive diagnostic tools and identification of vaccine` candidate targets. In the current study, the anti-viral antibody response in transgenic K18-hACE-2 mice was examined by implementing an immunodominant epitope mapping approach of the SARS-CoV-2 spike. Serum samples for probing an epitope array covering the entire spike protein were collected from mice following infection with the original SARS-CoV-2 strain as well as the B.1.1.7 Alpha and B.1.351 Beta genetic variants of concern. The analysis resulted in distinction of six linear epitopes common to the humoral response against all virus variants inspected at a frequency of more than 20% of the serum samples. Finally, the universality of the response was probed by cross-protective in vitro experiments using plaque-reducing neutralization tests. The data presented here has important implications for prediction of the efficacy of immune countermeasures against emerging SARS-CoV-2 variants. MDPI 2022-02-07 /pmc/articles/PMC8875268/ /pubmed/35214711 http://dx.doi.org/10.3390/vaccines10020251 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Levy, Yinon
Alcalay, Ron
Zvi, Anat
Makdasi, Efi
Peretz, Eldar
Noy-Porat, Tal
Chitlaru, Theodor
Mandelboim, Michal
Mazor, Ohad
Rosenfeld, Ronit
Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses
title Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses
title_full Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses
title_fullStr Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses
title_full_unstemmed Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses
title_short Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses
title_sort immunodominant linear b-cell epitopes of sars-cov-2 spike, identified by sera from k18-hace2 mice infected with the wt or variant viruses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875268/
https://www.ncbi.nlm.nih.gov/pubmed/35214711
http://dx.doi.org/10.3390/vaccines10020251
work_keys_str_mv AT levyyinon immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses
AT alcalayron immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses
AT zvianat immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses
AT makdasiefi immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses
AT peretzeldar immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses
AT noyporattal immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses
AT chitlarutheodor immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses
AT mandelboimmichal immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses
AT mazorohad immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses
AT rosenfeldronit immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses